CoChat

Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients

Jiang, Fanrong, Yan, Huadong, Liang, Lili, Du, Jingyuan, Jin, Susu, Yang, Shiqing, Wang, Hongxia, Hu, Ting, Zhu, Yuying, Wang, Guangming, Hu, Yaoren, Cai, Ting, Aithal, Guruprasad P. · 2021 · Liver International
Cited by 79

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background and Aims: Anti‐tuberculosis drugs remain as an important cause of drug‐induced liver injury (DILI) worldwide. Adverse drug reactions reduce the effectiveness of treatment. We aimed to determine the incidence and risk factors associated with anti‐tuberculosis DILI (ATDILI). Methods: Using established criteria and causality assessment methods, risk factors for ATDILI were identified in a contemporary cohort and validated in another cohort prospectively. Independent determinants of ATDILI were identified using Cox regression analysis. Results: In the derivation cohort (n = 3155), 170 (5.4%) developed ATDILI of which 27 (15.9%) developed jaundice; 9(5.3%) developed acute liver failure (ALF) and 3 died. Among HBsAg positive patients, 11/27 (40.7%) of ATDILI developed after 3 months of starting treatment. In addition, of 218 (6.9%) who developed raised alanine transferase (ALT) levels ≥3 times upper limit normal, 193 (88.5%) resolved and 25 (11.4%) progressed to DILI. Age (HR = 1.014, 95% CI: 1.005‐1.023), baseline ALT (HR = 1.014, 95% CI: 1.003‐1.024), haemoglobin (HR = 1.011, 95% CI: 1.002‐1.020) and HBsAg positivity (HR = 1.516, 95% CI: 1.004‐2.290) were independent risk factors for DILI. In the second cohort (n = 1497) of which 85 (5.7%) developed ATDILI. Age (HR = 1.029, 95% CI: 1.003‐1.056), baseline AST (HR = 1.036, 95% CI: 1.010‐1.062), previous TB treatment (HR = 3.894, 95% CI: 1.304‐11.625) and active drinking (HR = 3.624, 95% CI: 1.147‐11.454) were risk factors for developing jaundice. Conclusion: Elevation of ALT of ≥3 × ULN during anti‐TB treatment resolves in the vast majority without developing serious consequences. In two cohorts involving 4652 patients, incidence of ALF and death because of ATDILI are low. Age, baseline ALT, haemoglobin and HBsAg positivity are risk factors for the development of DILI and these inform monitoring and management of these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.14896

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 29

  1. WHO, 2019, Global tuberculosis report 2019
  2. 10.1186/1471-2458-10-267 · DOI
  3. 10.1016/S0140-6736(04)16764-0 · DOI
  4. 10.1016/S0140-6736(04)17141-9 · DOI · Paper page
  5. 10.1007/s00228-012-1429-9 · DOI · Paper page
  6. 10.1002/hep.510310129 · DOI · Paper page
  7. 10.1086/598929 · DOI · Paper page
  8. 10.1186/1471-2458-4-68 · DOI · Paper page
  9. 10.1002/hep.23534 · DOI · Paper page
  10. 10.1002/hep.23805 · DOI
  11. 10.1186/s12916-018-1033-7 · DOI · Paper page
  12. 10.1164/rccm.201105-0850OC · DOI · Paper page
  13. 10.1186/s12879-017-2330-z · DOI · Paper page
  14. 10.1016/j.jceh.2012.12.001 · DOI · Paper page
  15. World Health Organization, 2009, Treatment of Tuberculosis: Guidelines for National Programmes
  16. 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  17. 10.1038/clpt.2011.58 · DOI · Paper page
  18. 10.1016/S0016-5085(19)32568-5 · DOI · Paper page
  19. 10.1111/liv.12988 · DOI · Paper page
  20. 10.1002/hep.29283 · DOI · Paper page
  21. 10.1111/j.1440-1746.2012.07279.x · DOI · Paper page
  22. 10.1136/thx.51.2.132 · DOI · Paper page
  23. Singla R, 2010, Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity, Indian J Med Res, 132, 81
  24. 10.1136/bmj.38050.593634.63 · DOI · Paper page
  25. 10.1016/j.cgh.2018.12.013 · DOI · Paper page
  26. 10.1016/j.ajpath.2011.03.029 · DOI
  27. 10.1086/313809 · DOI · Paper page
  28. 10.5604/01.3001.0012.0920 · DOI
  29. 10.1016/j.jhep.2011.05.027 · DOI

Cited by

See all 79

Metadata

Authors
Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., Hu, Y., Cai, T., & Aithal, G. P.
Affiliations
  • Department of Pharmacy Hwamei Hospital University of Chinese Academy of Sciences Ningbo Institute of Life and Health Industry Ningbo China
  • Department of Infectious Diseases Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province Hwamei Hospital University of Chinese Academy of Sciences Ningbo Institute of Life and Health Industry Ningbo China
  • Department of Infectious Diseases Wenling Hospital University of Wenzhou School of Medicine Taizhou China
  • NIHR Nottingham Biomedical Research Centre Nottingham University Hospitals NHS Trust and University of Nottingham Nottingham UK
Venue
Liver International
Publisher
Wiley
Published
2021-05-03
Volume
41
Issue
7
Pages
1565-1575
ISSN
  • 1478-3223
  • 1478-3231
Cited by
79
References
5
Language
en
Funders
Natural Science Foundation of Zhejiang Province (LGF20H030006)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. https://app.cochat.ai/papers/10.1111/liv.14896
The paper
Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., Hu, Y., Cai, T., & Aithal, G. P. (2021). Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver International. https://doi.org/10.1111/liv.14896

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.